The nitric oxide hypothesis of aging

Nitric oxide (NO), generated by endothelial (e) NO synthase (NOS) and neuronal (n) NOS, plays a ubiquitous role in the body in controlling the function of almost every, if not every, organ system. Bacterial and viral products, such as bacterial lipopolysaccharide (LPS), induce inducible (i) NOS synthesis that produces massive amounts of NO toxic to the invading viruses and bacteria, but also host cells by inactivation of enzymes leading to cell death. The actions of all forms of NOS are mediated not only by the free radical oxidant properties of this soluble gas, but also by its activation of guanylate cyclase (GC), leading to the production of cyclic guanosine monophosphate (cGMP) that mediates many of its physiological actions. In addition, NO activates cyclooxygenase and lipoxygenase, leading to the production of physiologically relevant quantities of prostaglandin E2 (PGE2) and leukotrienes. In the case of iNOS, the massive release of NO, PGE2, and leukotrienes produces toxic effects. Systemic injection of LPS causes induction of interleukin (IL)-1 beta mRNA followed by IL-beta synthesis that induces iNOS mRNA with a latency of two and four hours, respectively, in the anterior pituitary and pineal glands, meninges, and choroid plexus, regions outside the blood-brain barrier, and shortly thereafter, in hypothalamic regions, such as the temperature-regulating centers, paraventricular nucleus containing releasing and inhibiting hormone neurons, and the arcuate nucleus, a region containing these neurons and axons bound for the median eminence. We are currently determining if LPS similarly activates cytokine and iNOS production in the cardiovascular system and the gonads. Our hypothesis is that recurrent infections over the life span play a significant role in producing aging changes in all systems outside the blood-brain barrier via release of toxic quantities of NO. NO may be a major factor in the development of coronary heart disease (CHD). Considerable evidence has accrued indicating a role for infections in the induction of CHD and, indeed, patients treated with a tetracycline derivative had 10 times less complications of CHD than their controls. Stress, inflammation, and infection have all been shown to cause induction of iNOS in rats, and it is likely that this triad of events is very important in progression of coronary arteriosclerosis leading to coronary occlusion. Aging of the anterior pituitary and pineal with resultant decreased secretion of pituitary hormones and the pineal hormone, melatonin, respectively, may be caused by NO. The induction of iNOS in the temperature-regulating centers by infections may cause the decreased febrile response in the aged by loss of thermosensitive neurons. iNOS induction in the paraventricular nucleus may cause the decreased nocturnal secretion of growth hormone (GH) and prolactin that occurs with age, and its induction in the arcuate nucleus may destroy luteinizing hormone-releasing hormone (LHRH) neurons, thereby leading to decreased release of gonadotropins. Recurrent infections may play a role in aging of other parts of the brain, because there are increased numbers of astrocytes expressing IL-1 beta throughout the brain in aged patients. IL-1 and products of NO activity accumulate around the plaques of Alzheimer's, and may play a role in the progression of the disease. Early onset Parkinsonism following flu encephalitis during World War I was possibly due to induction of iNOS in cells adjacent to substantia nigra dopaminergic neurons leading to death of these cells, which, coupled with ordinary aging fall out, led to Parkinsonism. The central nervous system (CNS) pathology in AIDS patients bears striking resemblance to aging changes, and may also be largely caused by the action of iNOS. Antioxidants, such as melatonin, vitamin C, and vitamin E, probably play an important acute and chronic role in reducing or eliminating the oxidant damage produced by NO.

[1]  S. Mccann,et al.  Nitric oxide inhibits hypothalamic luteinizing hormone-releasing hormone release by releasing gamma-aminobutyric acid. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[2]  S. Mccann,et al.  Nitric oxide mediates norepinephrine-induced prostaglandin E2 release from the hypothalamus. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[3]  S. Mccann,et al.  The Role of Nitric Oxide in Reproduction , 1996, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[4]  M. Wong,et al.  Inducible nitric oxide synthase gene expression in the brain during systemic inflammation , 1996, Nature Medicine.

[5]  H. Braak,et al.  A sex difference in neurodegeneration of the human hypothalamus , 1996, Neuroscience Letters.

[6]  S. Abramson,et al.  A novel mechanism of action of tetracyclines: effects on nitric oxide synthases. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[7]  W. L. Dees,et al.  Role of nitric oxide in the control of luteinizing hormone-releasing hormone release in vivo and in vitro. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[8]  S. Mccann,et al.  Ethanol inhibits luteinizing hormone-releasing hormone (LHRH) secretion by blocking the response of LHRH neuronal terminals to nitric oxide. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[9]  S. Mccann,et al.  Nitric oxide inhibits the release of norepinephrine and dopamine from the medial basal hypothalamus of the rat. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[10]  S. Mccann,et al.  Inhibition of nitric oxide synthase in the hypothalamus blocks the increase in plasma prolactin induced by intraventricular injection of interleukin-1 alpha in the rat. , 1994, Neuroimmunomodulation.

[11]  A. Camm,et al.  Elevated Chlamydia pneumoniae Antibodies, Cardiovascular Events, and Azithromycin in Male Survivors of Myocardial Infarction , 1997 .

[12]  J. Danesh,et al.  Chronic infections and coronary heart disease: is there a link? , 1997, The Lancet.

[13]  Role of nitric oxide in control of prolactin release by the adenohypophysis. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[14]  S. Snyder,et al.  Huntingtin-associated protein (HAP1): discrete neuronal localizations in the brain resemble those of neuronal nitric oxide synthase. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[15]  J. Knoll Sexual performance and longevity , 1997, Experimental Gerontology.

[16]  P. Emson,et al.  Immobilization-induced stress activates neuronal nitric oxide synthase (nNOS) mRNA and protein in hypothalamic-pituitary-adrenal axis in rats , 1996, Brain Research.

[17]  T. Dawson,et al.  Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[18]  F. Murad,et al.  Nitric Oxide and Cyclic GMP Signaling , 1996, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[19]  B. O’Malley,et al.  Nitric oxide mediates sexual behavior in female rats. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[20]  S. Mccann,et al.  Glutamic acid induces luteinizing hormone releasing hormone release via alpha receptors , 1995, Brain Research Bulletin.

[21]  C. Tirolo,et al.  Circadian melatonin and young-to-old pineal grafting postpone aging and maintain juvenile conditions of reproductive functions in mice and rats , 1997, Experimental Gerontology.

[22]  D. Hajjar,et al.  Virus-induced atherosclerosis. Herpesvirus infection alters aortic cholesterol metabolism and accumulation. , 1986, The American journal of pathology.

[23]  K. Lyson,et al.  Role of nitric oxide in interleukin 2-induced corticotropin-releasing factor release from incubated hypothalami. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[24]  S. Mccann,et al.  The nitric oxide hypothesis of brain aging , 1997, Experimental Gerontology.

[25]  W. Banks,et al.  Passage of cytokines across the blood-brain barrier. , 1995, Neuroimmunomodulation.

[26]  S. Snyder,et al.  Localization of nitric oxide synthase indicating a neural role for nitric oxide , 1990, Nature.

[27]  A. Camm,et al.  Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. , 1998, Circulation.

[28]  T. Kirkwood,et al.  Network theory of aging , 1997, Experimental Gerontology.

[29]  J. Garthwaite,et al.  Endothelium-derived relaxing factor release on activation of NMDA receptors suggests role as intercellular messenger in the brain , 1988, Nature.

[30]  M. Aguila Growth hormone-releasing factor increases somatostatin release and mRNA levels in the rat periventricular nucleus via nitric oxide by activation of guanylate cyclase. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[31]  V. Rettori,et al.  Role of nitric oxide in control of growth hormone release in the rat. , 1994, Neuroimmunomodulation.

[32]  S. Mccann,et al.  Adenosine acts by A1 receptors to stimulate release of prolactin from anterior-pituitaries in vitro. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[33]  S. Mccann,et al.  An interleukin-1-alpha-like neuronal system in the preoptic-hypothalamic region and its induction by bacterial lipopolysaccharide in concentrations which alter pituitary hormone release. , 1994, Neuroimmunomodulation.

[34]  S. Mccann,et al.  Oxytocin stimulates the release of luteinizing hormone-releasing hormone from medial basal hypothalamic explants by releasing nitric oxide. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[35]  S. Mccann,et al.  Nitric oxide mediates leptin-induced luteinizing hormone-releasing hormone (LHRH) and LHRH and leptin-induced LH release from the pituitary gland. , 1997, Endocrinology.

[36]  O. Hungnes,et al.  Chronic infections and coronary heart disease , 1997, The Lancet.

[37]  S. Moncada,et al.  Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor , 1987, Nature.

[38]  E. Gurfinkel,et al.  Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS pilot study , 1997, The Lancet.